Lupin 2024

PANTHERx Specialty Pharmacy

Centene completes acquisition of PANTHERx Rare Pharmacy

Centene completes acquisition of PANTHERx Rare Pharmacy

ST. LOUIS — Centene Corp. has completed its acquisition of PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases. “We are pleased to welcome the PANTHERx team to the Centene family,” said Michael F. Neidorff, chairman, president and chief executive officer for Centene. “PANTHERx is a

PANTHERx selected by Otsuka to distribute Jynarque

PANTHERx selected by Otsuka to distribute Jynarque

PITTSBURGH — PANTHERx Specialty Pharmacy has been selected by Otsuka America Pharmaceutical, Inc.  to distribute Jynarque (tolvaptan), the only FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD). PANTHERx is one of just three pharmacies providing nationwide access to the medication. ADPKD is one of the most common, life-threatening genetic diseases, diagnosed

PP_1170x120_10-25-21